Everglades Biopharma is a leader in developing ligand-based therapies. A proprietary technology of ligandomics enables systematic identification of disease-specific cellular ligands as therapeutic targets. Therapies can be rationally developed by overexpressing beneficial ligands or blocking detrimental ligands. Therapies against disease-specific ligands is expected to have higher therapeutic efficacy and less side effects than against non-disease-specific ligands.
A leading product of the Company is a therapeutic antibody against a novel angiogenic ligand that is upregulated in neovascular disease conditions but not expressed in normal vessels. This antibody drug is under development for the therapy of neovascular age-related macular degeneration (AMD), diabetic macular edema and cancer. |
